- Home
- CMCL vs RIGL Comparison
CMCL vs RIGL Comparison
Compare CMCL & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMCL | RIGL |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.5M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CMCL | RIGL |
|---|---|---|
| Price | $26.28 | $43.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $28.00 | ★ $43.20 |
| AVG Volume (30 Days) | 227.0K | ★ 560.9K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | 908.66 | ★ 2698.26 |
| EPS | 2.58 | ★ 6.20 |
| Revenue | $228,245,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $55.55 | $65.53 |
| Revenue Next Year | $7.57 | $0.22 |
| P/E Ratio | $10.13 | ★ $6.91 |
| Revenue Growth | 38.04 | ★ 79.13 |
| 52 Week Low | $8.81 | $15.50 |
| 52 Week High | $38.75 | $52.24 |
Technical Indicators
Market Signals| Indicator | CMCL | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 48.18 |
| Support Level | $26.15 | $41.54 |
| Resistance Level | $27.41 | $43.56 |
| Average True Range (ATR) | 1.33 | 1.63 |
| MACD | 0.30 | -0.32 |
| Stochastic Oscillator | 70.02 | 39.03 |
Price Performance
Historical ComparisonAbout CMCL Caledonia Mining Corporation Plc
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. The company's project includes Maligreen and Motapa.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.